PPWP
ALNY icon

Premier Path Wealth Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Premier Path Wealth Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-596
Closed -$237K – 399
2025
Q4 		$237K Buy
596
+92
+18% +$40.7K 0.03% 363
2025
Q3 		$230K Buy
+504
New +$205K 0.03% 370

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Premier Path Wealth Partners's ALNY Position: Q1 2026 in Review

Premier Path Wealth Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 596 shares — an estimated $237K sold.

Premier Path Wealth Partners first reported a position in ALNY in Q3 2025 and held it in 2 quarters. The position peaked at $237K in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Premier Path Wealth Partners reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Premier Path Wealth Partners sold 596 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $237K.
  • Premier Path Wealth Partners first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Premier Path Wealth Partners's Alnylam Pharmaceuticals position peaked at $237K in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Premier Path Wealth Partners's 13F filing for Q1 2026, filed 23 Apr 2026.